Boston Scientific price target raised to $78 from $70 at RBC Capital

RBC Capital raised the firm’s price target on Boston Scientific to $78 from $70 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 earnings for Medical Devices. The sector fundamentals are “flashing positive signals” and the firm is expecting strong results, the analyst tells investors in a research note. RBC adds that its checks continue to be notably positive on PFA adoption and shift from RF/Cryo, the pace of ramp, the company’s market share and pull through to the rest of the portfolio.